Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurazepam is a long-acting benzodiazepine derivative used primarily for the short-term treatment of insomnia, including difficulty falling asleep, frequent nocturnal awakenings, and early morning awakenings. It acts as a central nervous system depressant by binding to an allosteric site on the Gamma-aminobutyric acid type A receptor, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA) and increasing chloride ion influx into neurons. This results in hyperpolarization and decreased neuronal excitability. Flurazepam produces an active metabolite with a long half-life, which can lead to residual sedative effects ("hangover") the next day. Its pharmacological profile includes anxiolytic, anticonvulsant, hypnotic, sedative, and muscle relaxant properties[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Flurazepam.